<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711503</url>
  </required_header>
  <id_info>
    <org_study_id>2007-007146-34</org_study_id>
    <secondary_id>EudraCT 2007-007146-34</secondary_id>
    <secondary_id>Danish EthicalH-D-2008-060</secondary_id>
    <secondary_id>Danish Datatilsyn2007-41-1652</secondary_id>
    <secondary_id>JDRF file no. 17-2007-1804</secondary_id>
    <nct_id>NCT00711503</nct_id>
  </id_info>
  <brief_title>Anti-Interleukin-1 in Diabetes Action</brief_title>
  <acronym>AIDA</acronym>
  <official_title>A Randomised Clinical Trial of the Effect of Interleukin-1 Receptor Antagonism on the Insulin Production in Patients With New Onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oeresund Diabetes Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A draw trial of the effect of Interleukin-1 Receptor Antagonist (anakinra, Kineret®) on the&#xD;
      insulin production in patients with new onset Type 1 diabetes.&#xD;
&#xD;
      Kineret® is already being used in the treatment of patients suffering from rheumatoid&#xD;
      arthritis and preclinical studies are now suggesting that it may also be useful for patients&#xD;
      with Type 1 diabetes. The active substance in Kineret is interleukin-1 receptor antagonist, a&#xD;
      blocker of an immune-signal molecule named interleukin-1.&#xD;
&#xD;
      The trial is a blinded randomised trial, in which the patient is allocated to receive the&#xD;
      active drug (Kineret®) or placebo (saline). The hypothesis is that anti-IL-1 treatment as&#xD;
      add-on therapy to conventional insulin therapy will preserve or enhance beta-cell function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the&#xD;
      feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining&#xD;
      or enhancing beta-cell function in people with new onset Type 1 diabetes.&#xD;
&#xD;
      Trial Design:&#xD;
&#xD;
      A randomized, placebo controlled, double masked, parallel group, multicentre trial of IL-1&#xD;
      antagonism in subjects with newly-diagnosed Type 1 diabetes. Patients are instructed to&#xD;
      inject 100 mg human recombinant interleukin-1 receptor antagonist (anakinra, Kineret®, Amgen,&#xD;
      CA) or placebo s.c. once daily for 2 years. Endpoints will be evaluated every three months,&#xD;
      with an interim analysis after 6 months.&#xD;
&#xD;
      Trial population:&#xD;
&#xD;
      The design will be a two-stage phase 2a study to address feasibility, safety/tolerability and&#xD;
      potential efficacy. In the first phase 80 patients between 18 and 35 years of age with new&#xD;
      on-set Type 1 diabetes will be randomized to anakinra or placebo, and endpoints will be&#xD;
      analyzed as an interim analysis after 6 months by an independent data and safety monitoring&#xD;
      board (DSMB). A futility analysis will be performed at this time point to prevent&#xD;
      continuation of the trial if it shows no likelihood of demonstrating efficacy. In the event&#xD;
      the trial does show promise of efficacy considering the power of the first phase based on a&#xD;
      conditional analysis the DSMB can recommend prolongation of the study with recruitment to&#xD;
      ensure adequate power, and that additional funding is provided.&#xD;
&#xD;
      Methods and interventions:&#xD;
&#xD;
      The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human&#xD;
      non-glycosylated interleukin-1 receptor antagonist (anakinra) at a dose of 100 mg once daily&#xD;
      or placebo by subcutaneous injection at the same time-point in the morning. Primary and&#xD;
      secondary endpoints and safety parameters are investigated after 1 month and then every 3&#xD;
      months.&#xD;
&#xD;
      Safety:&#xD;
&#xD;
      Anakinra is FDA approved for the indication rheumatoid arthritis and has an acceptable risk /&#xD;
      benefit profile in this indication, with more than 100.000 patients treated. Most common&#xD;
      ad-verse events include mild and transient local injection reactions in 20-50% of subjects&#xD;
      treated with Anakinra. Consistent with its mechanism of action, anakinra reduces WBC/ANC in&#xD;
      2.4% of patients and this may increase the risk of infection. Accordingly, treatment with&#xD;
      anakinra will not be initiated in patients with active infections. Safety will be monitored&#xD;
      by physical exams and blood and urine tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Δ 2-h AUC C-peptide response</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental and/or peak C-peptide response, Time to peak C-peptide, insulin requirement per kg body weight per day,frequency of insulin free state with maintenance of HbA1c &lt;7.5%, HbA1c, Means of fasting glucose values, circulating IL-6 and CRP</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients are instructed to administer placebo by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anakinra</intervention_name>
    <description>The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>The patients are instructed to administer placebo (saline) once daily by subcutaneous injection</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes diagnosed according to WHO 1999 criteria&#xD;
&#xD;
          -  Positive GAD auto-antibodies&#xD;
&#xD;
          -  Age 18-35 yrs at onset of diabetes&#xD;
&#xD;
          -  Time from first symptoms of diabetes &lt; 12 weeks&#xD;
&#xD;
          -  Peak C-peptide more than or equal to 200 pM after a standardized mixed meal test&#xD;
             (Boost) at a test carried out when the subject is metabolically stable, i.e. after&#xD;
             resolution of any polyuria, polydypsia or ketoacidosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe liver or renal disease (creatinine &gt; 100 μmol/L, ASAT/ALAT &gt; 2* ULN, alkaline&#xD;
             phosphatase &gt; 2 * ULN)&#xD;
&#xD;
          -  History of heart disease, signs of cardiac failure or abnormal ECG&#xD;
&#xD;
          -  Present or previous malignancy&#xD;
&#xD;
          -  Pregnancy or failure of fertile female to comply with contraceptional planning, or&#xD;
             breast-feeding. (Safe contraceptive methods include birth control pills, IUD, and&#xD;
             gestagen implants) . Plans of pregnancy within 2 years.&#xD;
&#xD;
          -  Participation in other clinical intervention studies&#xD;
&#xD;
          -  Anti-inflammatory therapy (except aspirin £ 100 mg/d)&#xD;
&#xD;
          -  Active infections (CRP&gt;30), history of recurrent infection or predisposition to&#xD;
             infections&#xD;
&#xD;
          -  Neutropenia: ANC &lt; 1.5*109/L, or anaemia: Haemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
          -  Immune-suppressive treatment or immune-deficiency&#xD;
&#xD;
          -  Presence at diagnosis of late diabetic complications&#xD;
&#xD;
          -  Concurrent vaccination with live vaccine. Known need for live vaccinations within 2&#xD;
             years.&#xD;
&#xD;
          -  Use of Etanercept within 6 months before screening or during the double-blinded study&#xD;
             period&#xD;
&#xD;
          -  Hypersensitivity to E. coli-derived proteins, anakinra or any components of the&#xD;
             product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Mandrup-Poulsen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Donath</last_name>
    <role>Study Director</role>
    <affiliation>Universtity of Zürich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flemming Pociot, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Dinarello</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edwin Gale, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Bristol University, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Universitetshospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400 NV</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital, Hillerød</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm University, Dept. of Internal Medicine</name>
      <address>
        <city>Ulm</city>
        <state>Donau</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leibniz Center for Diabetes research, Heinrich-Heine University</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Diabetesforschung, Munich University of Technology</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Campus Bio-Medico</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Bialystok</name>
      <address>
        <city>Bialystok</city>
        <zip>15-269</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces, Diabetes Research Group</name>
      <address>
        <city>Barakaldo</city>
        <state>Bizkaia</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitario Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnua de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Slovenia</country>
    <country>Sweden</country>
  </removed_countries>
  <reference>
    <citation>Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial--background and rationale. Diabetes Metab Res Rev. 2009 May;25(4):321-4. doi: 10.1002/dmrr.960. Review. Erratum in: Diabetes Metab Res Rev. 2009 Nov;25(8):780.</citation>
    <PMID>19405081</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>August 31, 2012</last_update_submitted>
  <last_update_submitted_qc>August 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Lise Tarnow</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>endogenous insulin production</keyword>
  <keyword>C-peptide level</keyword>
  <keyword>insulin requirement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

